Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in cisplatin-based chemotherapy: A randomized controlled trial

Japanese Journal of Clinical Oncology

Volumn 35, Issue 12, 2005, Pages 695-699

  Cheirsilpa, Arkom ^a   Sinthusake, Tanadej ^b   Songsakkaesorn, Apinya ^b   Visawaprasit, Somchit ^b   Chulaka, Kemachit ^b   Changkuingdee, Nunchaporn ^b  

^a NATIONAL CANCER INSTITUTE   (Thailand)

^b Mahavajiralongkorn Cancer Center   (Thailand)

Author keywords

Chemotherapy; Cisplatin; Granisetron; Nausea and vomiting; Ramosetron

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; FLUOROURACIL; GRANISETRON; RAMOSETRON;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG FEVER; DRUG SAFETY; DYSPEPSIA; FEMALE; FLUSHING; HEADACHE; HICCUP; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NAUSEA AND VOMITING; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH PAIN; THAILAND; THORAX PAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CISPLATIN; DIZZINESS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; FEMALE; GRANISETRON; HEADACHE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; VOMITING, ANTICIPATORY;

EID: 30744463264     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi192     Document Type: Article

References (9)

1. Gralla RJ, Osoba D, Kris MG, Kirbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17:2971-94.
2. Miyata K, Kamato T, Nishda A, Ito H, Katsuyama Y, Iwai A, Yuki H, Yamano M, Tsutsumi R, Ohta M, et al. Pharmacologic profile of R-5-[(1-mehtyl-3-indolyl)carbonyl]-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride (YM060), a potent and selective 5-hydrotryptamine3 receptor antagonist, and its enantiomer in the isolated tissue. J Pharmacol Exp Ther 1991;259:15-21.
3. Ito H, Hidaka K, Miyata K, Kamato Y, Nishida A, Honda K. Characterization of YM060, a potent and selective 5-hydroxytryptamine3 receptor antagonist, in rabbit nodose ganglion and N1E-115 neuroblastoma cells. J Pharmacol Exp Ther 1992;263:1127-32.
4. Fujihara A, Tanaka S, Suzuki M, Yamamoto M, Asano M. The effect of YM060, a novel 5-HT3 receptor antagonist, on 5-HT-induced Bezold-Jarisch reflex in ferrets. Clin Rep 1994;2:2329-35.
5. Fujihara A, Tanaka S, Suzuki M, Yamamoto M, Asano M. The effect of YM060, a novel 5-HT3 receptor antagonist, on cisplatin-induced emesis in ferret. Clin Rep 1994;28:2337-47.
6. Fujihara A, Tanaka S, Suzuki M, Yamamoto M, Asano M. The effect of YM060, a novel 5-HT3 receptor antagonist on cisplatin-induced nausea and vomiting. Clin Rep 1994;28:2329-35.
7. Noda K, Ikeda M, Yoshida O, Yano S, Taguchi T, Shimoyama T, et al. Clinical phase-III trial of YM060 injection in the treatment of nausea and vomiting induced by the antineoplastic agent: A single-blind comparative study with granisetron as the control. J New Rem Clin 1994;43:2241-55.
8. Mori S, Takaya K, Hyouba R. Clinical evaluation of YM060 injection on chemotherapy-induced nausea and emesis: Study on preventive administration method. J Adult Dis 1994;24:2257-65.
9. Koizumi W, Satoshi T, Shizuka N, Katsuhiko H, Norisuke N, Katsunori S, et al. A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: Is patient preference a better primary endpoint? Chemotherapy 2003;49:316-23.